Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Panel Unanimously Backs Regeneron Eye Drug

By Pharmaceutical Processing | June 20, 2011

WASHINGTON (AP) — A panel of federal health experts voted
unanimously in favor of a new eye drug from Regeneron, bringing the company one
step closer to competing against a blockbuster Roche drug that currently
dominates the market.

A Food and Drug Administration advisory panel voted 10-0
Friday that Regeneron’s drug is a safe and effective treatment for a condition
that can lead to blindness in seniors, according to an agency spokeswoman. More
than 200,000 new cases of the condition, called wet macular degeneration, are
diagnosed each year.

The FDA is not required to follow the group’s advice, though
it often does.

If approved, Regeneron’s injectable drug will be the first
product to compete with Roche’s Lucentis, which posts sales of $1.5 billion
annually. The FDA is scheduled to make its final decision on approval by Aug.
20. If approved, Regeneron and its partner Bayer Pharmaceuticals will co-market
the drug under the brand name Eylea.

Analysts have high expectations for Regeneron’s drug because
it requires fewer injections than Lucentis: once every two months, versus once
a month. Company executives say the extended dosing regimen should appeal to
both doctors and patients.

Shares of Tarrytown, N.Y.-based Regeneron Pharmaceuticals
Inc. were halted from trading pending the panel vote.

Wet, age-related macular degeneration is the most common
cause of blindness among older Americans. The condition causes new blood
vessels to grow in the eye and leak blood and fluid, damaging the retina and
distorting vision.

The “dry” form of the condition is the most common
type of macular degeneration, with the “wet” form considered the more
advanced version of the disease.

Regeneron may face its toughest competition from another
Roche drug called Avastin, which is chemically similar to Lucentis. Avastin is
a cancer drug that doctors have used for many years to treat the eye disease
even though it is not approved for that purpose. Specially-formulated
injections of Avastin cost just $50, compared with $2,000 for Lucentis.

Regeneron executives have not yet discussed how they will
price their drug.

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE